Verastem, Inc.
NASDAQ:VSTMBiotechnology
-$0.00 today
- Market cap
- $865.72M
- Beta
- 0.27
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.97
Volume 3.97M
Average 2.58M
VSTM Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Verastem, Inc.NASDAQ: VSTM
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue remains negative
Q1 FY2026 revenue was $18.67M, compared with $0 a year earlier. Trailing-twelve-month revenue was $49.59M. Over 3 fiscal years it compounded at +128.4% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 6 analysts of $109.95M (+255.7%) for the fiscal year ending Dec 2026, a step up from the +209.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $18.67M+6.5% QoQ
- Last fiscal yearDec 2025
- $30.91M+209.1% YoY
- LTMMar 2026
- $49.59M+395.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | +970.6% | — |
| 1 year | +209.1% | +255.7% | +46.5 pp |
| 3-year CAGR | +128.4% | +90.4% | -38.0 pp |
| 5-year CAGR | +78.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 30.91M USD
- Year-over-year change
- +209.1%
- 4-year CAGR
- +97.0%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.91M | +209.1% |
| FY2024 | 2024-12-31 | 10M | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 2.6M | +26.4% |
| FY2021 | 2021-12-31 | 2.05M | — |
Revenue vs competitors
How VSTM compares with its peers on the latest reported figures
- VSTM's LTM Mar 2026 revenue of $49.59M is the 2nd highest of the 11 companies compared; the peer median is $3.51M.
- Its year-over-year change of +395.8% is the 2nd highest of 6, against a peer median of +20.1%.
- Over three fiscal years its annual growth of +128.4% compares with a peer median of +15.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $169.9M | +1083.6% | — | |
| LTM Mar 2026 | $49.59M | +395.8% | +128.4% | |
| LTM Mar 2026 | $34.86M | -12.4% | +5.0% | |
| LTM Mar 2026 | $28.22M | +20.1% | +17.1% | |
| LTM Mar 2026 | $16.72M | +138.9% | — | |
| LTM Jun 2024 | $6.49M | — | — | |
| LTM Mar 2026 | $525K | -10.7% | +15.4% | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $0 | — | — |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 | — | — |
| Peer median (excluding VSTM) | $3.51M | +20.1% | +15.4% | |
Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.05M | 2.6M | 0 | 10M | 30.91M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 5.3M |
| Gross Profit | 2.05M | 2.6M | 0 | 10M | 25.62M |
| Gross Margin | 100.0% | 100.0% | — | 100.0% | 82.9% |
| Research & Development | 39.35M | 50.56M | 61.36M | 81.33M | 114.6M |
| Selling, General & Admin | 24.12M | 24.98M | 30.73M | 43.62M | 81.15M |
| Operating Expenses | 63.46M | 75.53M | 92.08M | 124.96M | 195.75M |
| Depreciation & Amortization | 72K | 118K | 62K | 26K | 728K |
| EBITDA | (61.16M) | (71.56M) | (83.17M) | (125.86M) | (207.61M) |
| EBITDA Margin | -2978.9% | -2756.4% | — | -1258.6% | -671.6% |
| Operating Income | (61.41M) | (72.94M) | (92.08M) | (114.96M) | (170.13M) |
| Operating Margin | -2991.2% | -2809.6% | — | -1149.6% | -550.3% |
| Interest Income | 181K | 1.22M | 6.21M | 4.15M | 4.07M |
| Interest Expense | 9.97M | 2.14M | 4.14M | 4.56M | 1.14M |
| Other Income / Expenses | (9.79M) | (875K) | 4.72M | (15.5M) | (39.34M) |
| Income Before Tax | (71.2M) | (73.81M) | (87.37M) | (130.45M) | (209.47M) |
| Pre-Tax Margin | -3468.1% | -2843.3% | — | -1304.5% | -677.6% |
| Income Tax Expense | 0 | 0 | 0 | 185K | 0 |
| Net Income | (71.2M) | (73.81M) | (87.37M) | (130.64M) | (209.47M) |
| Net Margin | -3468.1% | -2843.3% | — | -1306.4% | -677.6% |
| EPS (Basic) | (4.92) | (4.57) | (3.96) | (3.66) | (3.02) |
| EPS (Diluted) | (4.92) | (4.57) | (3.96) | (3.66) | (3.02) |
| Weighted Avg Shares | 14.53M | 16.14M | 22.05M | 35.71M | 69.31M |
| Weighted Avg Shares (Diluted) | 14.53M | 16.14M | 22.05M | 35.71M | 69.31M |
Verastem, Inc.
NASDAQ:VSTM
Intrinsic Alpha fair value
Locked
Current Price
$6.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.